Antibacterial Agents TRIZ Cases

Malassezia-derived compositions reduce bacterial growth by 10-fold, addressing antibiotic resistance in Staphylococcus infections.

Xanthan gum and chitosan encapsulation protects live probiotics from oxygen and heat stress, maintaining microbial viability without refrigeration.

Substituted N-[(4,5-diphenylpyrimidin-2-yl)methyl]amine derivatives provide targeted antagonistic activity at CB1 cannabinoid receptors.

Colloidal silicon dioxide compensates for flavoring-induced deterioration of tablet hardness and stability, ensuring mechanical integrity.

Electroporation delivery of MRSA PBP2a DNA vaccines overcomes insufficient intramuscular immune responses.

Formula I compounds inhibit TBK and IKKε kinases, resolving the trade-off between treatment efficacy and selective targeting.

Low-dose radiation creates emissive filament-like structures on Mycobacterium single cell bacteria to enhance immunogenicity.

Hyaluronan chloramide reacts with iodides to generate active iodine species in aqueous environments.

Formula I N-heterotricyclic antibiotics overcome antimicrobial resistance in Gram-negative and Gram-positive strains while minimizing hERG channel inhibition.

Targeting Chlamydia MOMP to the E. coli outer membrane via a leader sequence resolves insolubility and misfolding, yielding native-like antigenic structures.

Formula I dihydrofuro pyrimidines inhibit AKT kinase signaling, resolving the lack of effective targeted therapies for hyperproliferative cancers.

A fusion protein system uses the avian Orthoreovirus muNS Intercoil domain to detect molecular interactions.

Formula I-A compounds inhibit indoleamine 2,3-dioxygenase to counteract immune suppression and neurotoxicity.

Structural modifications to oxazolidinones reduce toxicity while maintaining efficacy against Mycobacterium tuberculosis.

Cytokine-secreting ECS cells reverse periodontal tissue damage by stimulating natural healing pathways instead of relying on invasive surgical interventions.

High-viscosity carriers adhere to the gastric mucosa, improving penetration effectiveness and eradication rates while maintaining patient compliance.

Highly purified 2'-fucosyllactose and related compounds selectively promote beneficial microbes, addressing the inadequacy of current prebiotic agents.

Alkaline phosphatase converts lipopolysaccharides and CpG DNA into non-toxic forms, resolving the trade-off between antibiotic adhesion and survival rates.

A dynamic stimulation platform modulates drug characteristics to measure time-varying cellular responses.

Heat-resistant Lactobacillus binds mutans Streptococci to form removable aggregates, addressing gaps in coverage against non-mutans species.

Furopyridine derivatives inhibit Syk and BTK kinases, preventing tumor immune evasion and resistance mechanisms.

Clinoptilolite particles inhibit pathogenic germs while promoting lactobacilli growth, restoring vaginal microbiome balance.

Intramammary polyether ionophores treat mastitis by disrupting bacterial membranes through cation exchange, addressing antibiotic resistance and toxicity.

Disubstituted beta-amino acids create cytolytic peptides that maintain stability and reduce toxicity against multi-resistant bacteria.

Triglycerides with 15-55% sn-2 palmitic acid enhance mucosal weight and barrier function to resolve gastrointestinal disorders in preterm infants.

Peptide inhibitors bind to the AniA nitrite reductase active site, blocking anaerobic respiration and biofilm formation in Neisseria gonorrhoeae.

Novel Salmonella bacteriophage ΦCJ2 targets pathogenic bacteria with acid and heat stability for feed and water applications.

Escalating IL-15/IL-15Rα heterodimer doses maintain effective ratios to enhance immune function without systemic toxicity.

A thiazolidone spiro pyrimidine trione compound enhances in vivo and in vitro antibacterial activity through specific structural modifications.

Replacing beta-lactam cores with novel scaffolds evades bacterial resistance mutations while maintaining high affinity inhibition of resistant enzyme mutants.

Modified Vaccinia virus Ankara stimulates protective immune responses through replication-incompetent design.

High-affinity antibodies bind Bacillus anthracis protective antigen to neutralize toxins via intramuscular administration.

Mannitol replaces human serum albumin to prevent anaphylactic responses while maintaining viral infectivity during frozen storage.

A synthetic peptide forms pores in microbial membranes to kill bacteria and promote wound healing.

Esters and metal salts of 2-hydroxy-4-propylcyclohepta-2,4,6-trienone preserve biological activity while resisting thermal degradation.

Weak base solutions adjust pH to 4.0-7.0, converting micafungin acid into sodium salt while preventing degradation impurities.

Modified antimicrobial peptides utilize modular design to enhance stability and transport across biological barriers.

Phenyltriazoles inhibit B-Raf V600E kinase to reduce cancer cell proliferation while maintaining favorable pharmacokinetic properties.

Nitrogen containing bicyclic compounds overcome beta-lactamase resistance mechanisms to treat infections.

HNGAL muteins bind calcitonin gene-related peptide with high affinity through targeted amino acid substitutions.

High-affinity human monoclonal antibodies block PD-L1 interactions to reverse T regulatory cell suppression and enhance immune responses against tumors.

Alkyl polyglucosides combined with lauric acid destroy Streptococcus agalactiae without inducing antibiotic resistance.

Liposomes feature localized polyethylene glycol regions to maintain colloidal stability while enabling direct bacterial cell interaction.